-
Knowledge-Informed Machine Learning for Cancer Diagnosis and Prognosis: A review
Authors:
Lingchao Mao,
Hairong Wang,
Leland S. Hu,
Nhan L Tran,
Peter D Canoll,
Kristin R Swanson,
**g Li
Abstract:
Cancer remains one of the most challenging diseases to treat in the medical field. Machine learning has enabled in-depth analysis of rich multi-omics profiles and medical imaging for cancer diagnosis and prognosis. Despite these advancements, machine learning models face challenges stemming from limited labeled sample sizes, the intricate interplay of high-dimensionality data types, the inherent h…
▽ More
Cancer remains one of the most challenging diseases to treat in the medical field. Machine learning has enabled in-depth analysis of rich multi-omics profiles and medical imaging for cancer diagnosis and prognosis. Despite these advancements, machine learning models face challenges stemming from limited labeled sample sizes, the intricate interplay of high-dimensionality data types, the inherent heterogeneity observed among patients and within tumors, and concerns about interpretability and consistency with existing biomedical knowledge. One approach to surmount these challenges is to integrate biomedical knowledge into data-driven models, which has proven potential to improve the accuracy, robustness, and interpretability of model results. Here, we review the state-of-the-art machine learning studies that adopted the fusion of biomedical knowledge and data, termed knowledge-informed machine learning, for cancer diagnosis and prognosis. Emphasizing the properties inherent in four primary data types including clinical, imaging, molecular, and treatment data, we highlight modeling considerations relevant to these contexts. We provide an overview of diverse forms of knowledge representation and current strategies of knowledge integration into machine learning pipelines with concrete examples. We conclude the review article by discussing future directions to advance cancer research through knowledge-informed machine learning.
△ Less
Submitted 12 January, 2024;
originally announced January 2024.
-
RZiMM-scRNA: A regularized zero-inflated mixture model framework for single-cell RNA-seq data
Authors:
Xinlei Mi,
William Bekerman,
Peter A. Sims,
Peter D. Canoll,
Jianhua Hu
Abstract:
Applications of single-cell RNA sequencing in various biomedical research areas have been blooming. This new technology provides unprecedented opportunities to study disease heterogeneity at the cellular level. However, unique characteristics of scRNA-seq data, including large dimensionality, high dropout rates, and possibly batch effects, bring great difficulty into the analysis of such data. Not…
▽ More
Applications of single-cell RNA sequencing in various biomedical research areas have been blooming. This new technology provides unprecedented opportunities to study disease heterogeneity at the cellular level. However, unique characteristics of scRNA-seq data, including large dimensionality, high dropout rates, and possibly batch effects, bring great difficulty into the analysis of such data. Not appropriately addressing these issues obstructs true scientific discovery. Herein, we propose a unified Regularized Zero-inflated Mixture Model framework designed for scRNA-seq data (RZiMM-scRNA) to simultaneously detect cell subgroups and identify gene differential expression based on a developed importance score, accounting for both dropouts and batch effects. We conduct extensive simulation studies in which we evaluate the performance of RZiMM-scRNA and compare it with several popular methods, including Seurat, SC3, K-Means, and Hierarchical Clustering. Simulation results show that RZiMM-scRNA demonstrates superior clustering performance and enhanced biomarker detection accuracy compared to alternative methods, especially when cell subgroups are less distinct, verifying the robustness of our method. Our empirical investigations focus on two brain tumor studies dealing with astrocytoma of various grades, including the most malignant of all brain tumors, glioblastoma multiforme (GBM). Our goal is to delineate cell heterogeneity and identify driving biomarkers associated with these tumors. Notably, RZiMM-scNRA successfully identifies a small group of oligodendrocyte cells which has drawn much attention in biomedical literature on brain cancers.
△ Less
Submitted 25 October, 2021;
originally announced October 2021.
-
Substituting Gadolinium in Brain MRI Using DeepContrast
Authors:
Haoran Sun,
Xueqing Liu,
Xinyang Feng,
Chen Liu,
Nanyan Zhu,
Sabrina J. Gjerswold-Selleck,
Hong-Jian Wei,
Pavan S. Upadhyayula,
Angeliki Mela,
Cheng-Chia Wu,
Peter D. Canoll,
Andrew F. Laine,
J. Thomas Vaughan,
Scott A. Small,
Jia Guo
Abstract:
Cerebral blood volume (CBV) is a hemodynamic correlate of oxygen metabolism and reflects brain activity and function. High-resolution CBV maps can be generated using the steady-state gadolinium-enhanced MRI technique. Such a technique requires an intravenous injection of exogenous gadolinium based contrast agent (GBCA) and recent studies suggest that the GBCA can accumulate in the brain after freq…
▽ More
Cerebral blood volume (CBV) is a hemodynamic correlate of oxygen metabolism and reflects brain activity and function. High-resolution CBV maps can be generated using the steady-state gadolinium-enhanced MRI technique. Such a technique requires an intravenous injection of exogenous gadolinium based contrast agent (GBCA) and recent studies suggest that the GBCA can accumulate in the brain after frequent use. We hypothesize that endogenous sources of contrast might exist within the most conventional and commonly acquired structural MRI, potentially obviating the need for exogenous contrast. Here, we test this hypothesis by develo** and optimizing a deep learning algorithm, which we call DeepContrast, in mice. We find that DeepContrast performs equally well as exogenous GBCA in map** CBV of the normal brain tissue and enhancing glioblastoma. Together, these studies validate our hypothesis that a deep learning approach can potentially replace the need for GBCAs in brain MRI.
△ Less
Submitted 15 January, 2020;
originally announced January 2020.
